NCT06727721

Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Lu jin ，MD · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Umbilical cord mesenchymal stem cell injection expressing OCN19, while playing the role of MSCs, can directly stimulate the expression of insulin gene and the division and proliferation of islet beta cells, which is expected to further enhance the therapeutic effect of stem cells. In non-clinical studies, it was found that MSCs expressing OCN19 had better hypoglycemic effect than MSCs

Conditions

• Diabetes
• Type 2 Diabetes

Interventions

Type	Name	Description
BIOLOGICAL	mesenchymal stem cells with OCN-19	The patient received mesenchymal stem cells with OCN-19 three times
BIOLOGICAL	Mesenchymal stem cells	Ordinary mesenchymal stem cells were given
BIOLOGICAL	albumin injection	Placebo

Timeline

• Start date: 2023-11-06
• Primary completion: 2028-12-12
• Completion: 2029-12-12
• First posted: 2024-12-11
• Last updated: 2024-12-17

Locations

1 site across 1 country: China